Research
Hormonal
Bariatric endoscopy is becoming increasingly popular as a less invasive treatment option for obesity and associated nonalcoholic fatty liver disease (NAFLD).
Practitioners should consider bariatric endoscopy as a viable option for patients seeking less invasive weight loss solutions.
StrongSupportsmedium confidence
The massive expansion of bariatric endoscopy is driven by need: today, one-third of the world's population is overweight or obese and has associated nonalcoholic fatty liver disease (NAFLD).
Why this rating
The claim is supported by a broad observation of global health trends.
Source
The liver adventures of bariatric endoscopy
Ivo Boškoski · Endoscopy · 2023
DOI 10.1055/a-2160-1581
other
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →